AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
methacholine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1726 | 55-92-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A quaternary ammonium parasympathomimetic agent with the muscarinic actions of ACETYLCHOLINE. It is hydrolyzed by ACETYLCHOLINESTERASE at a considerably slower rate than ACETYLCHOLINE and is more resistant to hydrolysis by nonspecific CHOLINESTERASES so that its actions are more prolonged. It is used as a parasympathomimetic bronchoconstrictor agent and as a diagnostic aid for bronchial asthma. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1116)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 | 54 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,GRK2,MAPK7 | 7 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 31, 1986 | FDA | METHAPHARM |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V04CX03 | VARIOUS DIAGNOSTIC AGENTS OTHER DIAGNOSTIC AGENTS Other diagnostic agents |
| FDA MoA | N0000175369 | Cholinergic Agonists |
| CHEBI has role | CHEBI:35620 | vasodilator agent |
| CHEBI has role | CHEBI:38324 | cholinergic agonist |
| CHEBI has role | CHEBI:38325 | muscarinic agonist |
| CHEBI has role | CHEBI:50141 | bronchoconstrictor agent |
| CHEBI has role | CHEBI:53000 | epitope |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| MeSH PA | D008916 | Miotics |
| MeSH PA | D010277 | Parasympathomimetics |
| MeSH PA | D016085 | Bronchoconstrictor Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| MeSH PA | D018721 | Muscarinic Agonists |
| MeSH PA | D019141 | Respiratory System Agents |
| FDA EPC | N0000175884 | Cholinergic Receptor Agonist |
Related Drugs by ATC class:
V04CX Other diagnostic agents 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Diagnostic Test for Asthma | indication | ||
| Gastritis | contraindication | 4556007 | DOID:4029 |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Disorder of thyroid gland | contraindication | 14304000 | DOID:50 |
| Increased gastric tonus | contraindication | 18644006 | |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Body fluid retention | contraindication | 43498006 | |
| Bradycardia | contraindication | 48867003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
| Nasal polyp | contraindication | 52756005 | |
| Hepatic failure | contraindication | 59927004 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Factor II deficiency | contraindication | 73975000 | |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
| Hemophilia | contraindication | 90935002 | |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Breastfeeding (mother) | contraindication | 413712001 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | CHEMBL | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.23 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.80 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.64 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.23 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | AGONIST | EC50 | 6.40 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | EC50 | 6.92 | IUPHAR | ||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.80 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020262 | VUID |
| N0000148153 | NUI |
| D04970 | KEGG_DRUG |
| 62-51-1 | SECONDARY_CAS_RN |
| 4020262 | VANDF |
| 4020540 | VANDF |
| C0600370 | UMLSCUI |
| CHEBI:6804 | CHEBI |
| CHEMBL978 | ChEMBL_ID |
| DB06709 | DRUGBANK_ID |
| CHEMBL1200764 | ChEMBL_ID |
| D016210 | MESH_DESCRIPTOR_UI |
| 1993 | PUBCHEM_CID |
| 7438 | IUPHAR_LIGAND_ID |
| 03V657ZD3V | UNII |
| 155080 | RXNORM |
| 5064 | MMSL |
| 72376 | MMSL |
| d03667 | MMSL |
| 001688 | NDDF |
| 001689 | NDDF |
| 109196007 | SNOMEDCT_US |
| 372766003 | SNOMEDCT_US |
| 53584007 | SNOMEDCT_US |
| 3161 | INN_ID |
| 03V657ZD3V | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Provocholine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64281-100 | POWDER, FOR SOLUTION | 100 mg | RESPIRATORY (INHALATION) | NDA | 24 sections |
| Provocholine Inhalation Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64281-116 | SOLUTION | 48 mg | RESPIRATORY (INHALATION) | NDA | 24 sections |